

**Pentraxin-3 polymorphisms and invasive mold infections in acute leukemia patients receiving intensive chemotherapy**

Anne-Sophie Brunel,<sup>1\*</sup> Agnieszka Wójtowicz,<sup>1\*</sup> Frédéric Lamoit,<sup>1,2</sup> Olivier Spertini,<sup>3</sup> Dionysios Neofytos,<sup>4</sup> Thierry Calandra,<sup>1</sup> Oscar Marchetti<sup>1,5</sup> and Pierre-Yves Bochud<sup>1</sup>

<sup>1</sup>Infectious Diseases Service, Department of Medicine, Lausanne University Hospital (CHUV); <sup>2</sup>Microbiology Institute, Lausanne University Hospital (CHUV); <sup>3</sup>Hematology Service, Department of Oncology, Lausanne University Hospital (CHUV); <sup>4</sup>Infectious Diseases Service, University Hospital Geneva (HUG) and <sup>5</sup>Department of Medicine, Ensemble Hospitalier de la Côte, Morges, Switzerland.

\*ASB and AW contributed equally to this work.

Correspondence: Pierre-Yves.Bochud@chuv.ch  
doi:10.3324/haematol.2018.195453

## Supplementary Figure Legends

### Supplementary Figure 1.

Cumulative incidence of probable/proven invasive mold infections according to homozygosity for rs2305619 and/or rs3816527 PTX3 SNPs and underlying hematological condition. A) Courses starting in patients with acute myeloid leukemia and refractory anemia with excess blast type 2 (N=167); B) Courses starting in patients with acute lymphoblastic leukemia (N=45); C) All courses excluding those with previous allogeneic hematopoietic stem cells transplant (N=203). P value stands for the log rank test.


### Supplementary Figure 2.

Cumulative incidence of probable/proven invasive mold infections according to different combinations of rs2305619 and rs3816527 PTX3 SNPs. A) Homozygosity for the minor allele of both rs2305619 and rs3816527 versus the other; B) Homozygosity for the minor allele of rs2305619 versus the other; C) Homozygosity for the minor allele of rs3816527 versus the other. P value stands for the log rank test.

### Supplementary Figure 3.


Cumulative incidence of probable/proven invasive mold infections according to homozygosity for rs2305619 and/or rs3816527 PTX3 SNPs A) Courses with anti-mold prophylaxis were excluded; B) Courses with a possible mold infection were excluded; C) Courses with invasive mold infection due to molds other than *Aspergillus* spp were excluded. P value stands for the log rank test.

Supplementary Figure 1




N indicates the number of chemotherapy cycles at risk, F indicates the number of failures (i.e. invasive mold infections: IMI), CI indicates the 6 month cumulative incidence of IMI.

Supplementary Figure 2



N indicates the number of chemotherapy cycles at risk, F indicates the number of failures (i.e. invasive mold infections: IMI), CI indicates the 6 month cumulative incidence of IMI

Supplementary Figure 3



N indicates the number of chemotherapy cycles at risk, F indicates the number of failures (i.e. invasive mold infections: IMI), CI indicates the 6 month cumulative incidence of IMI

Supplementary Table 1

	<u>Model 1</u>			<u>Model 2</u>			<u>Model 3</u>		
	All patients (N=212)			All patients, interaction (N=212)			Patients without pre-existing neutropenia (N=133)		
	HR	95% CI	P	HR	95% CI	P	HR	95% CI	P
<b>Malignancy</b>									
Acute myeloid leukemia	Ref.			Ref.			Ref.		
Acute lymphoblastic leukemia	0.96	0.34-2.70	0.9	0.91	0.31-2.63	0.9	0.40	0.09-1.79	0.2
Refractory anemia with excess blast-2	2.77	0.97-7.90	0.06	2.35	0.82-6.70	0.1	1.52	0.40-5.81	0.5
<b>Homozygosity for <i>rs2305619</i> and/or <i>rs3816527</i></b>	2.06	0.94-4.54	0.07	4.47	1.49-13.4	0.007	5.06	1.68-15.24	0.04
<b>Pre-existing neutropenia<sup>a</sup></b>	1.28	0.56-2.93	0.6	2.95	0.98-8.92	0.06			
<b>Interaction variable<sup>b</sup></b>				0.16	0.03-0.91	0.04			

<sup>a</sup> Neutropenia was defined by an ANC<500/mm<sup>3</sup>.

<sup>b</sup> Interaction between homozygosity for *rs2305619* and/or *rs3816527* and pre-existing neutropenia.